On February 1, Novo Nordisk reported its 2018 results, with annual net income of 1118.3.1 billion DKK (177.$1 billion), up 5% from 2017, with Chinese revenue of 11.2%.8.5 billion DKK (17.$8.7 billion, + 8%), accounting for 10. 5% of the company's net income.1%.In 2018, Novo Nordisk invested 148.5 billion DKK (23.$4.5 billion), accounting for a proportion of income 13.2%, up from 2017.5.6%.
Liraglutide has been a global sales of hypoglycemic agents, but for price reasons, it has not been able to open up the Chinese market.After entering the national health insurance catalogue in 2017, liraglutide has a relatively significant volume in the Chinese market (see: how much can we increase the sales volume of drugs by entering medical insurance?), and the sales revenue increased by 73% in 2018, reaching 5.2.1 billion DKK (approximately $82.5 million), which has accounted for 87% of the total GLP-1 drug market in China and accounted for the entire diabetes drug market 1.A 3% share.
The future growth of Novo Nordisk is largely due to semaglutide (subcutaneous & oral), including the resulting obesity and NASH market opportunities.
Ozempic (semaglutide), as a once-weekly long-acting GLP-1 receptor agonist, was approved in February 2018 and is currently approved in 11 countries in North America and Europe, with a global revenue of 17 in 2018.9.6 billion DKK (2.$8.4 billion), which started off well.
The current phase III PIONEER project for oral somaglutide is also progressing well, and the PIONEER 9 study demonstrates that the hypoglycemic and weight-reducing effects of Japanese type 2 diabetes patients are better than liraglutide; it is better in the PIONEER 6 study. Cardiovascular safety and can significantly reduce cardiovascular mortality and all-cause mortality in patients with type 2 diabetes;
Novo Nordisk said in the financial report that it plans to submit a market application for oral somaglutide to the FDA in 2019Q1 and will use the priority review voucher (there is no report on the priority of Novo Nordisk from which company) Coupon), 2019H1 submitted a listing application for oral somaglutide to the European Union. In addition, Novo Nordisk is in close communication with the FDA and looks forward to applying data from the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes studies for an indication for cardiovascular risk reduction without the need for additional large cardiovascular outcomes studies with the oral formulation of semaglutide.